1-4 of 4
Horst Schran
Close
Sort by
Journal Articles

Pharmacokinetics of Nilotinib in Subjects with Normal or Impaired Hepatic Function.

Jaymes Holland, RPh, Chiaki Tanaka, PhD, Wei Zhou, PhD, Venkat Sethuraman, MS, Douglas M. Heuman, MD, Horst Schran
Journal: Blood
Blood (2007) 110 (11): 2379.
https://doi.org/10.1182/blood.V110.11.2379.2379
Published: 2007
Journal Articles

Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [ 14 C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects.

Mark Kagan, PhD, Phi Tran, M.Sc, Volker Fischer, PhD, Paula Savage, MS, Tom Smith, BS, Chiaki Tanaka, PhD, Horst Schran, PhD, Milind Narurkar, PhD, PharmD, Leila Alland, MD
Journal: Blood
Blood (2005) 106 (11): 4887.
https://doi.org/10.1182/blood.V106.11.4887.4887
Published: 2005
Journal Articles

The Effects of Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics (PK), Pharmacodynamics (PD), and Renal Function in Patients with Multiple Myeloma.

James R. Berenson, Pierre Major, Regina A. Swift, Robert Vescio, Christina Rivera, Sanela Bilic, Sonia Gauron, Jannick Denouel, Horst Schran
Journal: Blood
Blood (2005) 106 (11): 5192.
https://doi.org/10.1182/blood.V106.11.5192.5192
Published: 2005
Journal Articles

The Effect of Increasing Zoledronic Acid Dose and Infusion Rate on Pharmacokinetics, Pharmacodynamics, and Renal Function in Patients with Multiple Myeloma.

James Berenson, Pierre Major, Christina Ravera, Sanela Bilic, Horst Schran
Journal: Blood
Blood (2004) 104 (11): 4939.
https://doi.org/10.1182/blood.V104.11.4939.4939
Published: 2004